Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000, 160 (6): 809-815. 10.1001/archinte.160.6.809.
Article
CAS
PubMed
Google Scholar
Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR: Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006, 4 (3): 529-535. 10.1111/j.1538-7836.2006.01804.x.
Article
CAS
PubMed
Google Scholar
Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ: Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002, 162 (11): 1245-1248. 10.1001/archinte.162.11.1245.
Article
PubMed
Google Scholar
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000, 343 (25): 1846-1850. 10.1056/NEJM200012213432504.
Article
CAS
PubMed
Google Scholar
Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH: Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006, 24 (7): 1112-1118. 10.1200/JCO.2005.04.2150.
Article
PubMed
Google Scholar
Chew HK, Wun T, Harvey D, Zhou H, White RH: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006, 166 (4): 458-464. 10.1001/.458.
Article
PubMed
Google Scholar
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002, 100 (10): 3484-3488. 10.1182/blood-2002-01-0108.
Article
CAS
PubMed
Google Scholar
Krauth D, Holden A, Knapic N, Liepman M, Ansell J: Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer. 1987, 59 (5): 983-985. 10.1002/1097-0142(19870301)59:5<983::AID-CNCR2820590522>3.0.CO;2-O.
Article
CAS
PubMed
Google Scholar
Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000, 18 (17): 3078-3083.
CAS
PubMed
Google Scholar
Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008, 133 (6 Suppl): 381S-453S. 10.1378/chest.08-0656.
Article
CAS
PubMed
Google Scholar
AWMF 2010: [S3-Guideline: Prophylaxis of venous thromboembolism (VTE)]. [http://www.awmf.org/leitlinien/detail/ll/003-001.html]
Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW: American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007, 25 (34): 5490-5505. 10.1200/JCO.2007.14.1283.
Article
CAS
PubMed
Google Scholar
Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Jahanzeb M, Leung LL, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB: Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006, 4 (9): 838-869.
CAS
PubMed
Google Scholar
Mandala M, Falanga A, Roila F: Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. Ann Oncol. 2010, 21 (Suppl 5): v274-276.
Article
PubMed
Google Scholar
Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999, 341 (11): 793-800. 10.1056/NEJM199909093411103.
Article
CAS
PubMed
Google Scholar
Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004, 110 (7): 874-879. 10.1161/01.CIR.0000138928.83266.24.
Article
CAS
PubMed
Google Scholar
Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006, 332 (7537): 325-329. 10.1136/bmj.38733.466748.7C.
Article
CAS
PubMed
PubMed Central
Google Scholar
Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG: Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004, 164 (9): 963-968. 10.1001/archinte.164.9.963.
Article
PubMed
Google Scholar
Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004, 22 (10): 1944-1948. 10.1200/JCO.2004.10.002.
Article
CAS
PubMed
Google Scholar
Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005, 23 (10): 2130-2135. 10.1200/JCO.2005.03.134.
Article
CAS
PubMed
Google Scholar
Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004, 2 (8): 1266-1271. 10.1111/j.1538-7836.2004.00871.x.
Article
CAS
PubMed
Google Scholar
Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL: Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006, 81 (6): 758-767. 10.4065/81.6.758.
Article
CAS
PubMed
Google Scholar
Lazo-Langner A, Goss GD, Spaans JN, Rodger MA: The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2007, 5 (4): 729-737. 10.1111/j.1538-7836.2007.02427.x.
Article
CAS
PubMed
Google Scholar
Riess H, Haas S, Tebbe U, Gerlach H-E, Abletshauser C, Sieder C, Bramlage P, Schellong S: A randomized, double-blind, multicenter study of certoparin versus UFH to prevent venous thromboembolic events in acutely ill, non-surgical patients; The CERTIFY Study. J Thromb Haemost. 2010, 8 (6): 1209-1215. 10.1111/j.1538-7836.2010.03848.x.
Article
CAS
PubMed
Google Scholar
Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshauser C, Sieder C, Bramlage P, Riess H: Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: A subgroup analysis of the randomized, controlled CERTIFY study. Am Heart J. 2011, 161 (2): 322-328. 10.1016/j.ahj.2010.10.005.
Article
CAS
PubMed
Google Scholar
Rousson V, Seifert B: A mixed approach for proving non-inferiority in clinical trials with binary endpoints. Biom J. 2008, 50 (2): 190-204. 10.1002/bimj.200710410.
Article
PubMed
Google Scholar